Key result
Administration of the ET(A)-receptor antagonist LU135252 prevented angiotensin II-induced changes in vascular geometry and partially reduced the increase in blood pressure.
Why the study?
Does the ET(A)-receptor antagonist LU135252 prevent angiotensin II-induced vascular hypertrophy in vivo?
Population
In vivo model of angiotensin II-induced hypertrophy of small arteries
Comparison
Selective ET-receptor antagonist LU135252 in… vs Angiotensin II (200 ng x kg[-1] x min[-1]) alone
Design
Preclinical
Follow-up
Two weeks
Authors
Loading...
ET(A) antagonism may modulate Ang II vascular effects in animals; leaves open translation to human hypertension therapy.
Does the ET(A)-receptor antagonist LU135252 prevent angiotensin II-induced vascular hypertrophy in vivo?
Angiotensin II induces vascular hypertrophy via endothelin production, and ET(A)-receptor antagonism can prevent these structural changes.
Moreau et al. (1997) studied Angiotensin II-induced vascular hypertrophy. ET(A)-receptor antagonist LU135252 vs. Angiotensin II alone was evaluated on Changes in vascular geometry and blood pressure. Administration of the ET(A)-receptor antagonist LU135252 prevented angiotensin II-induced changes in vascular geometry and partially reduced the increase in blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: